The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
Crossref DOI link: https://doi.org/10.1186/s13045-016-0377-8
Published Online: 2017-01-05
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gravina, Giovanni Luca
Mancini, Andrea
Marampon, Francesco
Colapietro, Alessandro
Delle Monache, Simona
Sferra, Roberta
Vitale, Flora
Richardson, Peter J.
Patient, Lee
Burbidge, Stephen
Festuccia, Claudio